Trial watch: DNA-based vaccines for oncological indications Review uri icon


MeSH Major

  • Killer Cells, Natural
  • Neoplasm Metastasis
  • Neoplasms
  • Tumor Microenvironment


  • DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated. However, the clinical efficacy of DNA-based vaccines for cancer therapy is considerably limited by central and peripheral tolerance. During the past decade, considerable efforts have been devoted to the development and characterization of novel DNA-based vaccines that would circumvent this obstacle. In this setting, particular attention has been dedicated to the route of administration, expression of modified TAAs, co-expression of immunostimulatory molecules, and co-delivery of immune checkpoint blockers. Here, we review preclinical and clinical progress on DNA-based vaccines for cancer therapy.

publication date

  • December 2, 2017



  • Review



  • eng

PubMed Central ID

  • PMC5706602

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2017.1398878

PubMed ID

  • 29209575

Additional Document Info

start page

  • e1398878


  • 6


  • 12